Abstract | OBJECTIVE: To report the development of a spontaneous subcapsular splenic hematoma following filgrastim administration in a patient undergoing an allogeneic hematopoietic stem cell transplant. CASE SUMMARY: A 60-year-old female with myelodysplastic syndrome was admitted for a reduced-intensity allogeneic hematopoietic stem cell transplant from an unrelated donor. She received filgrastim 5 μg/kg starting on day 1 to accelerate neutrophil recovery. On day 5, she began reporting severe left chest-wall pain. Contrast-enhanced computed tomography of the abdomen/pelvis revealed a spontaneous subcapsular splenic hematoma. Upon discontinuation of filgrastim, the pain fully resolved. The patient was subsequently rechallenged with filgrastim, which led to recurrence of the left-sided chest-wall pain. Filgrastim was discontinued and the patient reported resolution of the pain. DISCUSSION: CONCLUSIONS:
|
Authors | Alex Ganetsky, Colleen Kucharczuk, Sarah Del Percio, Noelle Frey, Saar Gill |
Journal | The Annals of pharmacotherapy
(Ann Pharmacother)
Vol. 47
Issue 5
Pg. e22
(May 2013)
ISSN: 1542-6270 [Electronic] United States |
PMID | 23585644
(Publication Type: Case Reports, Journal Article)
|
Chemical References |
- Recombinant Proteins
- Granulocyte Colony-Stimulating Factor
- Filgrastim
|
Topics |
- Female
- Filgrastim
- Granulocyte Colony-Stimulating Factor
(adverse effects, therapeutic use)
- Hematoma
(chemically induced)
- Hematopoietic Stem Cell Transplantation
(methods)
- Humans
- Middle Aged
- Myelodysplastic Syndromes
(therapy)
- Recombinant Proteins
(adverse effects, therapeutic use)
- Splenic Diseases
(chemically induced)
|